beta thalassemia

Editas, changing course again, looks to partner lead CRISPR therapy

BioPharma Dive

Tue, 10/22/24 - 11:45 am

Editas Medicine

gene editing

CRISPR

reni-cel

sickle cell disease

beta thalassemia

FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia

BioPharma Dive

Wed, 01/17/24 - 09:34 am

Vertex Pharmaceuticals

With trial win for oral thalassemia drug, Agios charts broader path than gene therapy rivals

Fierce Pharma

Wed, 01/3/24 - 05:01 pm

Agios Pharmaceuticals

mitapivat

beta thalassemia

gene therapy

Vertex, CRISPR Win World’s First Approval for CRISPR-Edited Therapy from UK

BioSpace

Thu, 11/16/23 - 10:21 am

CRISPR

gene editing

Vertex Pharmaceuticals

CRISPR Therapeutics

Casgevy

beta thalassemia

First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results

Clinical Trials Arena

Thu, 08/3/23 - 06:28 pm

Vertex Pharmaceuticals

exa-cel

CRISPR

beta thalassemia

Pfizer to end license deal with Syros for blood disorder therapies

Reuters

Mon, 07/24/23 - 09:48 pm

Pfizer

Syros Pharmaceuticals

sickle cell disease

beta thalassemia

Gene Editing Race Between Editas and Vertex, CRISPR Heats Up

BioSpace

Mon, 06/12/23 - 09:58 am

gene editing

Editas Medicine

Vertex Pharmaceuticals

Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins, PDUFA date granted

Fierce Biotech

Fri, 06/9/23 - 10:07 am

Vertex Pharmaceuticals

Could This Move Make Vertex's Next Blockbuster Even Bigger?

Motley Fool

Wed, 04/12/23 - 11:34 am

Vertex Pharmaceuticals

exa-cel

beta thalassemia

sickle cell disease

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Yahoo/Businesswire

Mon, 04/3/23 - 10:09 am

Vertex Pharmaceuticals

Vertex given green light to seek US approval of CRISPR-based therapy

BioPharma Dive

Wed, 09/28/22 - 12:01 am

Vertex Pharmaceuticals

bluebird bio Scores First U.S. Approval for Lentiviral Vector Gene Therapy

BioSpace

Wed, 08/17/22 - 11:34 pm

Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact

Fierce Biotech

Wed, 06/22/22 - 10:23 am

Novartis

gene editing

Precision Biosciences

sickle cell disease

beta thalassemia

Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed PDUFA date

Endpoints

Mon, 06/6/22 - 11:45 pm

Bristol Myers Squibb

Reblozyl

beta thalassemia

FDA tags Editas' thalassemia cell therapy an orphan drug as it rounds final bend in race to clinic

Fierce Biotech

Sun, 05/15/22 - 11:19 pm

Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder

Fierce Biotech

Tue, 04/26/22 - 10:15 pm

Imara to reduce staff by 83% amid biotech shakeout

BioPharma Dive

Mon, 04/18/22 - 10:50 am

Imara’s two trial flops in blood disorders dim drug’s prospects in heart failure

MedCity News

Wed, 04/6/22 - 12:21 pm

Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl's anemia nod

Fierce Pharma

Fri, 03/25/22 - 10:33 am

Search form

You are here

beta thalassemia

Pages